| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 151, Issue 5 2444-2452, Copyright © 1993 by American Association of Immunologists
ARTICLES |
PT Mehrotra, D Wu, JA Crim, HS Mostowski and JP Siegel
Laboratory of Cellular Immunology, Food and Drug Administration, Bethesda, MD 20892.
We have studied the effects of human rIL-12 on the proliferation and generation of cytotoxic activity in human CTL precursors. Purified human blood CD8+ T lymphocytes were stimulated overnight with immobilized alpha-CD3 and cultured 3 to 4 additional days under various conditions. The addition of IL-12 resulted in a marked (10- to 20- fold), dose-dependent, augmentation of cytotoxicity per cell with a smaller (2-fold) increase in cell number. IL-12 augmentation of proliferation and cytotoxicity of CD8+ T cells was not inhibited by a mAb to the p55 subunit of the IL-2 receptor (alpha-Tac) at a concentration sufficient to block the activity of exogenously added IL- 2, indicating that the activity of IL-12 did not require IL-2. Addition of IL-12 at the time of alpha-CD3 activation or 1 day later was highly effective at augmenting cytotoxicity, whereas delayed addition of IL-12 (day 2 or 3) resulted in a smaller increase in CTL activity with no increase in cell number. IL-12 at all doses tested synergized with low dose IL-2 in inducing the proliferation and differentiation of CD8+ T cells. The synergistic effect was not blocked by adding neutralizing serum to IFN-gamma. In contrast to this synergistic effect, IL-12 significantly inhibited the proliferation observed in the presence of higher concentrations of IL-2 (4,500 and 13,500 pg/ml). An inhibitory effect of IL-12 was also observed when IL-12 was added to CD8+ T lymphocytes 3 days subsequent to activation with alpha-CD3 and IL-2. This broad set of potent effects of IL-12 on CD8+ T cell responses suggests that IL-12 may play an important immunoregulatory role on CTL development in vivo and may be a useful tool for manipulating this process in vivo for investigational and immunotherapeutic purposes.
This article has been cited by other articles:
|
|
 |
|
  R. F. Little, J. M. Pluda, K. M. Wyvill, I. R. Rodriguez-Chavez, G. Tosato, A. T. Catanzaro, S. M. Steinberg, and R. Yarchoan Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma Blood, June 15, 2006; 107(12): 4650 - 4657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. MacGregor, Q. Li, A. E. Chang, T. M. Braun, D. P.M. Hughes, and K. T. McDonagh Ex vivo Culture with Interleukin (IL)-12 Improves CD8+ T-Cell Adoptive Immunotherapy for Murine Leukemia Independent of IL-18 or IFN-{gamma} but Requires Perforin. Cancer Res., May 1, 2006; 66(9): 4913 - 4921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Acres, M. Gantzer, C. Remy, N. Futin, N. Accart, O. Chaloin, J. Hoebeke, J.-M. Balloul, and S. Paul Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity Cancer Res., October 15, 2005; 65(20): 9536 - 9546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pelloso, K. Cyran, L. Timmons, B. T. Williams, and M. J. Robertson Immunological Consequences of Interleukin 12 Administration after Autologous Stem Cell Transplantation Clin. Cancer Res., March 15, 2004; 10(6): 1935 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Peterson, H. Harlin, and T. F. Gajewski Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma J. Clin. Oncol., June 15, 2003; 21(12): 2342 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Smyth, P. P. Stapleton, C. B. Barden, J. R. Mestre, T. A. Freeman, M. D. Duff, S. Maddali, Z. Yan, and J. M. Daly Renal Cell Carcinoma Induces Prostaglandin E2 and T-Helper Type 2 Cytokine Production in Peripheral Blood Mononuclear Cells Ann. Surg. Oncol., May 1, 2003; 10(4): 455 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gri, E. Gallo, E. Di Carlo, P. Musiani, and M. P. Colombo OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes with GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response J. Immunol., January 1, 2003; 170(1): 99 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Eyles, D. Metcalf, M. J. Grusby, D. J. Hilton, and R. Starr Negative Regulation of Interleukin-12 Signaling by Suppressor of Cytokine Signaling-1 J. Biol. Chem., November 8, 2002; 277(46): 43735 - 43740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Robertson, D. Pelloso, R. Abonour, R. A. Hromas, R. P. Nelson Jr., L. Wood, and K. Cornetta Interleukin 12 Immunotherapy after Autologous Stem Cell Transplantation for Hematological Malignancies Clin. Cancer Res., November 1, 2002; 8(11): 3383 - 3393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Schnapp, C. S. Eickhoff, D. Sizemore, R. Curtiss III, and D. F. Hoft Cruzipain Induces Both Mucosal and Systemic Protection against Trypanosoma cruzi in Mice Infect. Immun., September 1, 2002; 70(9): 5065 - 5074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Schmidt and M. F. Mescher Peptide Antigen Priming of Naive, But Not Memory, CD8 T Cells Requires a Third Signal That Can Be Provided by IL-12 J. Immunol., June 1, 2002; 168(11): 5521 - 5529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wang, C. Feliciani, B. G. Howell, I. Freed, Q. Cai, H. Watanabe, and D. N. Sauder Contribution of Langerhans Cell-Derived IL-18 to Contact Hypersensitivity J. Immunol., April 1, 2002; 168(7): 3303 - 3308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Gorbachev, N. A. DiIulio, and R. L. Fairchild IL-12 Augments CD8+ T Cell Development for Contact Hypersensitivity Responses and Circumvents Anti-CD154 Antibody-Mediated Inhibition J. Immunol., July 1, 2001; 167(1): 156 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ito, J. Kurtz, J. Shaffer, and M. Sykes CD4 T Cell-Mediated Alloresistance to Fully MHC-Mismatched Allogeneic Bone Marrow Engraftment Is Dependent on CD40-CD40 Ligand Interactions, and Lasting T Cell Tolerance Is Induced by Bone Marrow Transplantation with Initial Blockade of this Pathway J. Immunol., March 1, 2001; 166(5): 2970 - 2981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Abe, T. Peng, J. Sailors, R. Bucala, and C. N. Metz Regulation of the CTL Response by Macrophage Migration Inhibitory Factor J. Immunol., January 15, 2001; 166(2): 747 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wigginton, J.-W. Park, M. E. Gruys, H. A. Young, C. L. Jorcyk, T. C. Back, M. J. Brunda, R. M. Strieter, J. Ward, J. E. Green, et al. Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis J. Immunol., January 15, 2001; 166(2): 1156 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Makrigiannis, B. L. Musgrave, S. M. M. Haeryfar, and D. W. Hoskin Interleukin-12 can replace CD28-dependent T-cell costimulation during nonspecific cytotoxic T lymphocyte induction by anti-CD3 antibody J. Leukoc. Biol., January 1, 2001; 69(1): 113 - 122. [Abstract] [Full Text]
|
|
|
|
|
|
B. W. Anderson, G. E. Peoples, J. L. Murray, M. A. Gillogly, D. M. Gershenson, and C. G. Ioannides Peptide Priming of Cytolytic Activity to HER-2 Epitope 369-377 in Healthy Individuals Clin. Cancer Res., November 1, 2000; 6(11): 4192 - 4200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Santin, P. L. Hermonat, A. Ravaggi, S. Bellone, S. Pecorelli, J. J. Roman, G. P. Parham, and M. J. Cannon Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes J. Virol., May 15, 2000; 74(10): 4729 - 4737. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Gollob, J. W. Mier, K. Veenstra, D. F. McDermott, D. Clancy, M. Clancy, and M. B. Atkins Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN-{{gamma}} Induction Is Associated with Clinical Response Clin. Cancer Res., May 1, 2000; 6(5): 1678 - 1692. [Abstract] [Full Text]
|
|
|
|
|
|
A. Schwarting, G. Tesch, K. Kinoshita, R. Maron, H. L. Weiner, and V. R. Kelley IL-12 Drives IFN-{gamma}-Dependent Autoimmune Kidney Disease in MRL-Faslpr Mice J. Immunol., December 15, 1999; 163(12): 6884 - 6891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Muraille, F. Andris, B. Pajak, K. M. Wissing, T. De Smedt, F. Desalle, M. Goldman, M.-L. Alegre, J. Urbain, M. Moser, et al. Downregulation of Antigen-Presenting Cell Functions After Administration of Mitogenic Anti-CD3 Monoclonal Antibodies in Mice Blood, December 15, 1999; 94(12): 4347 - 4357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Lukacher, J. M. Moser, A. Hadley, and J. D. Altman Visualization of Polyoma Virus-Specific CD8+ T Cells In Vivo During Infection and Tumor Rejection J. Immunol., September 15, 1999; 163(6): 3369 - 3378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Mullins, C. J. Burger, and K. D. Elgert Paclitaxel Enhances Macrophage IL-12 Production in Tumor-Bearing Hosts Through Nitric Oxide J. Immunol., June 1, 1999; 162(11): 6811 - 6818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Gollob, C. P. Schnipper, E. A. Murphy, J. Ritz, and D. A. Frank The Functional Synergy Between IL-12 and IL-2 Involves p38 Mitogen-Activated Protein Kinase and Is Associated with the Augmentation of STAT Serine Phosphorylation J. Immunol., April 15, 1999; 162(8): 4472 - 4481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Okamoto, K. Kohno, T. Tanimoto, H. Ikegami, and M. Kurimoto Development of CD8+ Effector T Cells Is Differentially Regulated by IL-18 and IL-12 J. Immunol., March 15, 1999; 162(6): 3202 - 3211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Curtsinger, C. S. Schmidt, A. Mondino, D. C. Lins, R. M. Kedl, M. K. Jenkins, and M. F. Mescher Inflammatory Cytokines Provide a Third Signal for Activation of Naive CD4+ and CD8+ T Cells J. Immunol., March 15, 1999; 162(6): 3256 - 3262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Farrar, K. H. Katz, J. Windsor, G. Thrush, R. H. Scheuermann, J. W. Uhr, and N. E. Street Cancer Dormancy. VII. A Regulatory Role for CD8+ T Cells and IFN-{gamma} in Establishing and Maintaining the Tumor-Dormant State J. Immunol., March 1, 1999; 162(5): 2842 - 2849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pardoux, X. Ma, S. Gobert, S. Pellegrini, P. Mayeux, F. Gay, G. Trinchieri, and S. Chouaib Downregulation of Interleukin-12 (IL-12) Responsiveness in Human T Cells by Transforming Growth Factor-beta : Relationship With IL-12 Signaling Blood, March 1, 1999; 93(5): 1448 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Robertson, C. Cameron, M. B. Atkins, M. S. Gordon, M. T. Lotze, M. L. Sherman, and J. Ritz Immunological Effects of Interleukin 12 Administered by Bolus Intravenous Injection to Patients with Cancer Clin. Cancer Res., January 1, 1999; 5(1): 9 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Biedermann and J. S. Pober Human Endothelial Cells Induce and Regulate Cytolytic T Cell Differentiation J. Immunol., November 1, 1998; 161(9): 4679 - 4687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. McFarland, P. A. Harding, S. MaWhinney, R. T. Schooley, and D. R. Kuritzkes In Vitro Effects of IL-12 on HIV-1-Specific CTL Lines from HIV-1-Infected Children J. Immunol., July 1, 1998; 161(1): 513 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Siders, P. W. Wright, J. A. Hixon, W. G. Alvord, T. C. Back, R. H. Wiltrout, and R. G. Fenton T Cell- and NK Cell-Independent Inhibition of Hepatic Metastases by Systemic Administration of an IL-12-Expressing Recombinant Adenovirus J. Immunol., June 1, 1998; 160(11): 5465 - 5474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Dey, Y.-G. Yang, G. L. Szot, D. A. Pearson, and M. Sykes Interleukin-12 Inhibits Graft-Versus-Host Disease Through an Fas-Mediated Mechanism Associated With Alterations in Donor T-Cell Activation and Expansion Blood, May 1, 1998; 91(9): 3315 - 3322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Mehrotra, R. P. Donnelly, S. Wong, H. Kanegane, A. Geremew, H. S. Mostowski, K. Furuke, J. P. Siegel, and E. T. Bloom Production of IL-10 by Human Natural Killer Cells Stimulated with IL-2 and/or IL-12 J. Immunol., March 15, 1998; 160(6): 2637 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Gollob, E. A. Murphy, S. Mahajan, C. P. Schnipper, J. Ritz, and D. A. Frank Altered Interleukin-12 Responsiveness in Th1 and Th2 Cells Is Associated With the Differential Activation of STAT5 and STAT1 Blood, February 15, 1998; 91(4): 1341 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-G. Yang, J. J. Sergio, D. A. Pearson, G. L. Szot, A. Shimizu, and M. Sykes Interleukin-12 Preserves the Graft-Versus-Leukemia Effect of Allogeneic CD8 T Cells While Inhibiting CD4-Dependent Graft-Versus-Host Disease in Mice Blood, December 1, 1997; 90(11): 4651 - 4660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ferrari, C. Berend, J. Ottinger, R. Dodge, J. Bartlett, J. Toso, D. Moody, J. Tartaglia, W. I. Cox, E. Paoletti, et al. Replication-Defective Canarypox (ALVAC) Vectors Effectively Activate Anti-Human Immunodeficiency Virus-1 Cytotoxic T Lymphocytes Present in Infected Patients: Implications for Antigen-Specific Immunotherapy Blood, September 15, 1997; 90(6): 2406 - 2416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Robertson and J. Ritz Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment Oncologist, February 1, 1996; 1(1): 88 - 97. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
